Epidemic of parvovirus B19 and disease severity in pregnant people, Denmark, January to March 2024

We report an epidemic of parvovirus B19 infections in Denmark during the first quarter of 2024, with a peak incidence 3.5 times higher than during the most recent epidemic in 2017. In total, 20.1% (130/648) of laboratory-confirmed cases were pregnant. Severe adverse outcomes were observed among 12.3...

Full description

Saved in:
Bibliographic Details
Published in:Euro surveillance : bulletin européen sur les maladies transmissibles 2024-06, Vol.29 (24)
Main Authors: Nordholm, Anne Christine, Trier Møller, Frederik, Fischer Ravn, Signe, Flink Sørensen, Lotte, Moltke-Prehn, Anja, Elskær Mollerup, Jacob, Funk, Tjede, Sperling, Lene, Jeyaratnam, Ulisa, Træholt Franck, Kristina, Hjort-Pedersen, Karina, Hjørnet Kamper, Christina, Thoft Nielsen, Rikke, Jokelainen, Pikka, Wessman, Maria
Format: Article
Language:English
Subjects:
Rapid Communication
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report an epidemic of parvovirus B19 infections in Denmark during the first quarter of 2024, with a peak incidence 3.5 times higher than during the most recent epidemic in 2017. In total, 20.1% (130/648) of laboratory-confirmed cases were pregnant. Severe adverse outcomes were observed among 12.3% (16/130) of pregnant people and included foetal anaemia, foetal hydrops and miscarriage. Parvovirus B19 infection is not systematically monitored, but a national laboratory-based surveillance system is currently being established in Denmark.We report an epidemic of parvovirus B19 infections in Denmark during the first quarter of 2024, with a peak incidence 3.5 times higher than during the most recent epidemic in 2017. In total, 20.1% (130/648) of laboratory-confirmed cases were pregnant. Severe adverse outcomes were observed among 12.3% (16/130) of pregnant people and included foetal anaemia, foetal hydrops and miscarriage. Parvovirus B19 infection is not systematically monitored, but a national laboratory-based surveillance system is currently being established in Denmark.
ISSN:1560-7917
1025-496X
1560-7917
DOI:10.2807/1560-7917.ES.2024.29.24.2400299